The following is a summary of the Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript:
Financial Performance:
Aethlon Medical had a cash balance of approximately $8 million as of December 31, 2023, and raised approximately $236,000 through common stock sales.
Consolidated operating expenses for the 3 months ending December 31, 2023, were about $3.6 million, up from $2.8 million in the same period the previous year.
The company saw a net loss increase to $3.6 million for the 3 months ending December 31, 2023, from $2.8 million in the same period the previous year.
Business Progress:
Aethlon Medical received clearance to conduct a Phase I trial for the Hemopurifier from the Drug Controller General of India and is set to begin following an in vitro binding study.
The company is exploring the use of Hemopurifier against viral infections through a COVID-19 trial in India.
Aethlon Medical is finalizing essentials for initiating oncology studies in India and Australia.
More details: Aethlon Medical IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.